Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, phase II study of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, doxorubicin, vincristine and dexamethasone alternated with bortezomib, rituximab, cytarabine and methotrexate in patients with newly diagnosed mantle cell lymphoma

Trial Profile

A prospective, phase II study of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, doxorubicin, vincristine and dexamethasone alternated with bortezomib, rituximab, cytarabine and methotrexate in patients with newly diagnosed mantle cell lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Rituximab; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 May 2018 New trial record
    • 03 May 2018 Results published in the Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top